A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors

被引：0
|
作者：
Hansen, M
Gimsing, P
Rasmussen, A
Jensen, PB
Knudsen, LM
机构：
[1] Rigshosp, DK-2100 Copenhagen, Denmark
[2] Topotarget AS, Copenhagen, Denmark
[3] Herlev Univ Hosp, Copenhagen, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：225S / 225S
页数：1
相关论文
共 50 条
  • [1] Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical studies and in a phase I study in patients with advanced haematological tumors.
    Gimsing, P
    Wu, F
    Qian, XZ
    Jeffers, M
    Knudsen, L
    Sehested, M
    Lichenstein, HS
    BLOOD, 2005, 106 (11) : 932A - 933A
  • [2] Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical prostate cancer studies
    Jeffers, M.
    Qian, X.
    Mills, E.
    LaRochelle, W.
    Lichenstein, H.
    Ara, G.
    EJC SUPPLEMENTS, 2006, 4 (12): : 109 - 109
  • [3] A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours.
    Steele, N
    Vidal, L
    Plumb, J
    Attard, G
    Rasmussen, A
    Buhl-Jensen, P
    Brown, R
    Blagden, S
    Evans, J
    de Bono, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 200S - 200S
  • [4] A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors
    Kelly, W. K.
    Yap, T.
    Lee, J.
    Lassen, U.
    Crowley, E.
    Clarke, A.
    Hawthorne, T.
    Buhl-Jensen, P.
    de Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical ovarian cancer studies.
    Qian, XZ
    LaRochelle, WJ
    Ara, G
    Wu, F
    Petersen, KD
    Thougaard, A
    Sehested, M
    Lichenstein, HS
    Jeffers, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9080S - 9080S
  • [6] A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors
    Molife, Rhoda
    Lee, James
    Petrylak, Daniel
    Blumenschein, George, Jr.
    Lassen, Ulrik
    Clark, Jayme
    Yap, Timothy
    Rowen, Elin
    Ang, Jooern
    Crowley, Elizabeth
    Clarke, Anne
    Hawthorne, Thomas
    Buhl-Jensen, Peter
    De Bono, Johann
    Kelly, Wm Kevin
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3476S - 3476S
  • [7] Updated results of the first in man evaluation of the histone deacetylase (HDAC) inhibitor, PXD101 in cancer patients (pts).
    de Bono, JS
    Steele, N
    Vidal, L
    Reid, A
    Marriott, C
    Tjornelund, J
    Shaw, H
    Plumb, J
    Molife, R
    Morrison, R
    Fong, P
    Buhl-Jensen, P
    Rasmussen, A
    Evans, TRJ
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9121S - 9121S
  • [8] Effect of the histone deacetylase (HDAC) inhibitor PXD101 on the human colon carcinoma cell line FET
    McArdle, Jessica K.
    Brattain, Michael
    Howell, Gillian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 757 - 757
  • [9] Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment
    Lin, Shu-Fu
    Lin, Jen-Der
    Chou, Ting-Chao
    Huang, Yu-Yao
    Wong, Richard J.
    PLOS ONE, 2013, 8 (10):
  • [10] Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
    Cashen, Amanda
    Juckett, Mark
    Jumonville, Alcee
    Litzow, Mark
    Flynn, P. J.
    Eckardt, John
    LaPlant, Betsy
    Laumann, Kristina
    Erlichman, Charles
    DiPersio, John
    ANNALS OF HEMATOLOGY, 2012, 91 (01) : 33 - 38
12345